// App-Quantinova.ai

3465 : Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the KarMMa Trial

Researchers

Presenter

  • Michel Delforge

Principal Investigators

  • Nina Shah

  • Paula Rodriguez-Otero

  • Parameswaran Hari

  • Julia Braverman

  • Andrew Trigg

  • Payal Patel

  • Liping Huang

  • Kristen Hege

  • Sujith Dhanasiri

Medical Centers

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Adelphi Values, Bollington, United Kingdom

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

Locations

  • Belgium

  • United States

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03361748

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved